A practical reference on size-exclusion chromatography: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
| Property | Value | Notes |
|---|---|---|
| Molar mass | approximately 4813 Da | calculated from the 39-residue sequence |
| Appearance | white to off-white powder | typical of lyophilised peptide material |
| Solubility class | freely soluble in water | measured value depends on salt form and pH |
| Plasma protein binding | >99 percent | linked to the fatty diacid side chain |
| Class | dual GIP and GLP-1 receptor agonist | receptor activity varies with the assay used |
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
At 250 °C, the peptide bond may be easily hydrolyzed, with its half-life dropping to about a minute. Protein may also be broken down without hydrolysis through pyrolysis; small heterocyclic compounds may start to form upon degradation. Above 500 °C, polycyclic aromatic hydrocarbons may also form, which is of interest in the study of generation of carcinogens in tobacco smoke and cooking at high heat.
== Works == Macleod was a prolific writer. His first academic article was a paper on phosphorus content in muscles published in 1899. During his career he authored or co-authored over 200 papers and eleven books. Among them are:
== Mixed martial arts == In 2009, Pudzianowski signed a contract with Konfrontacja Sztuk Walki – a Polish mixed martial arts organization – to take part in four fights. He debuted as a mixed martial arts fighter on 11 December 2009, during the KSW 12 event in Warsaw, Poland, winning against Marcin Najman. Pudzianowski started throwing low kicks soon after the fight began. After several hits, Najman fell to the mat and Pudzianowski started delivering punches (a tactic known as ground-and-pound). Najman was forced to tap the mat, indicating he wanted to end the fight, which lasted for only 43 seconds. Pudzianowski collected 200,000 zlotys (US$70,000) for the fight. On 7 May 2010, during the KSW 13 event, Pudzianowski won his second fight, against Yusuke Kawaguchi. The fight lasted two full rounds, with Pudzianowski winning by judges' decision. The fight was described as a "sloppy brawl". It was noted Pudzianowski had control over most of the fight, but was "neutralized" by Kawaguchi, and that, by the second round, he was looking "to be out of energy and breathing heavily". On 21 May 2010, Pudzianowski went on to participate in the Moosin: God of Martial Arts event, where he fought former two time UFC Heavyweight Champion Tim Sylvia. Pudzianowski fractured his metatarsus during the first round and then went on to deplete his stamina during the rest of the fight, which ultimately led to Sylvia defeating him via submission at 1:43 of round 2.
Sources: en.wikipedia.org
=== Avionics, military and government === In 1929 Vincent Bendix branched out into aeronautics and restructured the company as "Bendix Aviation" to reflect the new product lines. Bendix Aviation was founded as a holding company for the assets of Delco Aviation Corporation, Eclipse Machine Company, Stromberg Carburetor Company, and other aircraft accessory manufacturers. Bendix supplied aircraft manufacturers with hydraulic systems, for braking and flap activation, and introduced the pressure carburetor. It made a wide variety of electrical and electronic instruments for aircraft. From 1931, it sponsored the Bendix Trophy, a transcontinental U.S. point-to-point race intended to encourage the development of commercial aircraft. During and after World War II Bendix made radar equipment of various types. Bendix ranked 17th among United States corporations in the value of wartime production contracts. Bendix aviation masks and gauges were modified and tested for use in diving and hyperbaric applications. In the 1950s, Bendix and its successors managed United States Atomic Energy Commission facilities in Kansas City, Missouri and Albuquerque, New Mexico. These facilities procured non-nuclear components for nuclear weapons.
== Nuclear properties == Technetium-99m is a metastable nuclear isomer, as indicated by the "m" after its mass number 99. This means it is a nuclide in an excited (metastable) state that lasts much longer than is typical. The nucleus will eventually relax (i.e., de-excite) to its ground state through the emission of gamma rays or internal conversion electrons. These decays do not change the number of protons or neutrons, but only give them a lower-energy 'arrangement', which here is the ground state. The excitation energy above the ground state is 142.7 keV, but 99% of the time, it relaxes first to a slightly lower state (140.5 keV) by internal conversion (and the rate of this transition determines the uncertainty in half-life), which decays at once. In total, 99mTc decays about 89% by gamma emission (99mTc → 99Tc + γ) and almost all of the time, this results in a 140.5 keV gamma ray and only rarely in a 142.7 keV (1 in 4,000) as the latter decay, too, is very largely converted. The remaining 11% of decays are completed entirely by conversion and not of diagnostic utility, though still contributing to internal radiation dose. These gammas are the radiations that are picked up by a gamma camera when 99mTc is used as a radioactive tracer for medical imaging. Pure gamma emission is the desirable decay mode for medical imaging because other particles deposit more energy in the patient body (radiation dose) relatively to that in the camera. Metastable isomeric transition is the only nuclear decay mode that approaches pure gamma emission.
Medical preparations of insulin mix the peptide hormone with preservatives that adjust the pH and delay denaturation and absorption. Insulin analogues retain the hormone's function while providing improved absorption and biochemical activity. characteristics not currently possible with subcutaneously injected insulin proper. Insulin lispro, insulin aspart, and insulin glulisine are analogues that are rapidly absorbed to mimic real beta cell-produced insulin, while insulin detemir and insulin glargine are steadily absorbed to avoid a rapid decline in insulin action. However, meta-analyses conducted by Cochrane in 2005, Germany's Institute for Quality and Cost Effectiveness in the Health Care Sector [IQWiG] in 2007, and Canadian Agency for Drugs and Technology in Health (CADTH) also in 2007 have consistently shown that insulin analogues provide no clinical advantage over conventional insulin. However, insulin analogues are more temperature-resistant than human insulin, so they are preferred for clinical use in regions with limited refrigeration and extreme heat. Commonly used types of insulin are differentiated by the speed of their biochemical activity. Fast/rapid-acting insulin includes insulin analogues aspart, lispro, and glulisine. These begin to work within 5 to 15 minutes and are active for 3 to 4 hours. Most insulins form hexamers, which delay entry into the blood in active form; these analog insulins do not but have normal insulin activity.
Sources: en.wikipedia.org
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.
The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.
In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.